Valiltramiprosate

Summary

Valiltramiprosate (CHEMBL4650301) is a phase-3 clinical-stage small molecule; indicated across 1 condition including alzheimer disease.

At a glance

• Status: Max clinical phase 3 (not approved)
• Modality: Small molecule
• Indications: 1 condition
• Clinical trials: 3
• Chemistry: 238.31 Da · C8H18N2O4S

Identifiers

Drug identity and classification

Field	Value
ChEMBL ID	CHEMBL4650301
Name	Valiltramiprosate
Type	Small molecule
Max phase	3
FDA approved	no
PubChem CID	25008296
Molecular formula	C8H18N2O4S
Molecular weight	238.31
InChIKey	NRZRFNYKMSAZBI-ZETCQYMHSA-N

SMILES: CC(C)[C@@H](C(=O)NCCCS(=O)(=O)O)N

IUPAC name: 3-[[(2S)-2-amino-3-methylbutanoyl]amino]propane-1-sulfonic acid

Also known as: Alz-801, ALZ-801, BLU-8499, BLU8499, NRM-8499, NRM8499, Valiltramiprosate, VALILTRAMIPROSATE

Patent coverage: 52 distinct patent families (162 SureChEMBL compound mentions), from 1 matched compound structure(s). Mentions count patents naming the compound (not distinct inventions), so promiscuous / reference molecules inflate the mention figure — families are the dedup metric.

Targets

Targets

No target linkage available.

Bioactivity

No ChEMBL bioactivity rows at pChembl ≥ 5 (expected for biologics / antibodies).

Target pathways

No target-pathway data for this drug (no mapped target genes).

Indications & clinical

Indications

1 indication (0 at ChEMBL trial phase 4). Phase below is the highest clinical-trial phase recorded for this drug against each disease — not the molecule’s overall approval status (that is in the Summary).

Indication	Trial phase	MONDO	EFO
Alzheimer disease	3	MONDO:0004975	MONDO:0004975

Clinical trials

Total trials: 3.

Phase distribution

Phase	Trials
PHASE3	2
PHASE2	1

Top trials by phase / activity

NCT	Phase	Status	Title
NCT06304883	PHASE3	ACTIVE_NOT_RECRUITING	Long-term Extension of Phase 3 Study of ALZ- 801 in APOE4/4 Early AD Subjects
NCT04770220	PHASE3	COMPLETED	An Efficacy and Safety Study of ALZ-801 in APOE4/4 Early AD Subjects
NCT04693520	PHASE2	COMPLETED	Biomarker Effects of ALZ-801 in APOE4 Carriers With Early Alzheimer’s Disease

Clinical evidence (CIViC)

No CIViC predictive evidence (expected for non-precision-medicine drugs).

Pharmacology

Pharmacogenomics

No PharmGKB pharmacogenomic data curated for this drug.

Related molecules

Related molecules

No competitor molecules sharing a primary target (ChEMBL phase ≥2 or PubChem drug-class).